116 related articles for article (PubMed ID: 38539241)
1. Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients.
Barratt-Due A; Pettersen K; Børresdatter-Dahl T; Holter JC; Grønli RH; Dyrhol-Riise AM; Lerum TV; Holten AR; Tonby K; Trøseid M; Skjønsberg OH; Granerud BK; Heggelund L; Kildal AB; Schjalm C; Aaløkken TM; Aukrust P; Ueland T; Mollnes TE; Halvorsen B;
J Intern Med; 2024 Jul; 296(1):80-92. PubMed ID: 38539241
[TBL] [Abstract][Full Text] [Related]
2. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.
Holter JC; Pischke SE; de Boer E; Lind A; Jenum S; Holten AR; Tonby K; Barratt-Due A; Sokolova M; Schjalm C; Chaban V; Kolderup A; Tran T; Tollefsrud Gjølberg T; Skeie LG; Hesstvedt L; Ormåsen V; Fevang B; Austad C; Müller KE; Fladeby C; Holberg-Petersen M; Halvorsen B; Müller F; Aukrust P; Dudman S; Ueland T; Andersen JT; Lund-Johansen F; Heggelund L; Dyrhol-Riise AM; Mollnes TE
Proc Natl Acad Sci U S A; 2020 Oct; 117(40):25018-25025. PubMed ID: 32943538
[TBL] [Abstract][Full Text] [Related]
3. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.
Kowalska D; Kuźniewska A; Senent Y; Tavira B; Inogés S; López-Díaz de Cerio A; Pio R; Okrój M; Yuste JR
Front Immunol; 2022; 13():946522. PubMed ID: 36091057
[TBL] [Abstract][Full Text] [Related]
4. Increase in the Complement Activation Product C4d and the Terminal Complement Complex sC5b-9 Is Associated with Disease Severity and a Fatal Outcome in Necrotizing Soft-Tissue Infection.
Hedetoft M; Madsen MB; Hansen CB; Hyldegaard O; Garred P
J Innate Immun; 2022; 14(4):355-365. PubMed ID: 34903692
[TBL] [Abstract][Full Text] [Related]
5. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge.
Senent Y; Inogés S; López-Díaz de Cerio A; Blanco A; Campo A; Carmona-Torre F; Sunsundegui P; González-Martín A; Ajona D; Okrój M; Prósper F; Pio R; Yuste JR; Tavira B
Front Immunol; 2021; 12():767376. PubMed ID: 34868021
[TBL] [Abstract][Full Text] [Related]
6. Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes.
de Nooijer AH; Grondman I; Janssen NAF; Netea MG; Willems L; van de Veerdonk FL; Giamarellos-Bourboulis EJ; Toonen EJM; Joosten LAB;
J Infect Dis; 2021 Feb; 223(2):214-224. PubMed ID: 33038254
[TBL] [Abstract][Full Text] [Related]
7. Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study.
Charitos P; Heijnen IAFM; Egli A; Bassetti S; Trendelenburg M; Osthoff M
Front Immunol; 2021; 12():765330. PubMed ID: 34777382
[TBL] [Abstract][Full Text] [Related]
8. Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality.
Alosaimi B; Mubarak A; Hamed ME; Almutairi AZ; Alrashed AA; AlJuryyan A; Enani M; Alenzi FQ; Alturaiki W
Front Immunol; 2021; 12():668725. PubMed ID: 34276659
[TBL] [Abstract][Full Text] [Related]
9. Complement Activation in Kidneys of Patients With COVID-19.
Pfister F; Vonbrunn E; Ries T; Jäck HM; Überla K; Lochnit G; Sheriff A; Herrmann M; Büttner-Herold M; Amann K; Daniel C
Front Immunol; 2020; 11():594849. PubMed ID: 33584662
[TBL] [Abstract][Full Text] [Related]
10. Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality.
Defendi F; Leroy C; Epaulard O; Clavarino G; Vilotitch A; Le Marechal M; Jacob MC; Raskovalova T; Pernollet M; Le Gouellec A; Bosson JL; Poignard P; Roustit M; Thielens N; Dumestre-Pérard C; Cesbron JY
Front Immunol; 2021; 12():742446. PubMed ID: 34567008
[TBL] [Abstract][Full Text] [Related]
11. Systemic Inflammation and Complement Activation Parameters Predict Clinical Outcome of Severe SARS-CoV-2 Infections.
Huber S; Massri M; Grasse M; Fleischer V; Kellnerová S; Harpf V; Knabl L; Knabl L; Heiner T; Kummann M; Neurauter M; Rambach G; Speth C; Würzner R
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960645
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
13. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.
Sinkovits G; Mező B; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
Front Immunol; 2021; 12():663187. PubMed ID: 33841446
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation.
Jarlhelt I; Nielsen SK; Jahn CXH; Hansen CB; Pérez-Alós L; Rosbjerg A; Bayarri-Olmos R; Skjoedt MO; Garred P
Front Immunol; 2021; 12():767981. PubMed ID: 34804055
[TBL] [Abstract][Full Text] [Related]
15. A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce.
Laudanski K; Okeke T; Siddiq K; Hajj J; Restrepo M; Gullipalli D; Song WC
Sci Rep; 2022 Aug; 12(1):13658. PubMed ID: 35953544
[TBL] [Abstract][Full Text] [Related]
16. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins.
Ali YM; Ferrari M; Lynch NJ; Yaseen S; Dudler T; Gragerov S; Demopulos G; Heeney JL; Schwaeble WJ
Front Immunol; 2021; 12():714511. PubMed ID: 34290717
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
[TBL] [Abstract][Full Text] [Related]
18. Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.
Leatherdale A; Stukas S; Lei V; West HE; Campbell CJ; Hoiland RL; Cooper J; Wellington CL; Sekhon MS; Pryzdial ELG; Conway EM
Med Microbiol Immunol; 2022 Feb; 211(1):37-48. PubMed ID: 35034207
[TBL] [Abstract][Full Text] [Related]
19. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
20. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
